
Cytophage Expands Commercialization of Phage Products in Asian Poultry Market

Winnipeg, June 20, 2024. Cytophage Technologies Ltd. (TSXV:CYTO) (“**Cytophage**” or the “Company”), the only publicly traded phage company that is focused on bacteriophage solutions for both animal health and human health, announces that it has signed of a Letter of Intent (LOI) with a leading Pan-Asian industrial agrifood company headquartered in Singapore. The LOI outlines a collaboration pathway between Cytophage and this company that operates in six countries and derives approximately 80% of its multi-billion-dollar revenue from poultry operations. “Fully integrated poultry producers provide multifaceted opportunities for phage products – from eggs to feed to the chickens – creating an exciting environment in which to have our phage products improve production numbers by decreasing bacterial loads”, commented Cytophage CEO Dr. Steven Theriault. Cytophage anticipates conducting trials with this commercial partner in Q4 of 2024.

Cytophage continues to collaborate with its distribution partner in Bangladesh, recently introducing its innovative lyophilized tablet designed to replace the traditional liquid form commonly used in phage therapy. This new form is expected to increase product shelf life and product reliability in tropical zones. The Company recognizes the importance of regionalizing phage products to address local bacterial strains and environmental conditions in order to maximize product adoption and meet customer needs.

Cytophage also announces the departure of Chief Commercialization Officer (CCO) Michael Graham to pursue other endeavours. The recently established Commercialization Committee of the Board, together with Dr. Theriault and the commercialization team, will work to drive initiatives forward and expand Cytophage’s market presence. “We will continue to explore and secure new commercialization opportunities in various marketplaces” stated Dr. Theriault. “Our thanks go to Michael for his contributions in advancing the Company over the past six years and we wish him all the best for his future.”

Cytophage will hold its Annual General Meeting (AGM) on June 25, 2024. The AGM materials can be found on the Cytophage website at <https://cytophage.com/investors/#agm> This meeting will cover the business of the AGM. An investor presentation and update will be held at a later date.

For further information please contact:

Heather Medwick
Chief Operating Officer
heather@cytophage.com
431 388 8873

Cytophage Investor Alerts: <https://cytophage.com/subscribe/>

About Cytophage Technologies

Cytophage Technologies (**TSXV:CYTO**) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.